Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/22/24
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/21/24
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaGlobeNewsWire • 03/18/24
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024GlobeNewsWire • 03/15/24
Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceGlobeNewsWire • 03/13/24
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingGlobeNewsWire • 03/11/24
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseGlobeNewsWire • 03/04/24
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaGlobeNewsWire • 01/05/24
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 01/03/24
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 MillionGlobeNewsWire • 01/02/24
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 12/29/23
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.GlobeNewsWire • 12/06/23
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium TherapeuticsPRNewsWire • 12/06/23
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaGlobeNewsWire • 12/06/23
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/23
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/07/23
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023GlobeNewsWire • 10/31/23